Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries - Scorecard - MDSpire

Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries

  • By

  • Sophie Warren

  • Rafael Bolanos

  • Lucila Rey-Ares

  • Juan Manuel Reyes

  • Jose Luis Huerta

  • Alana Ranzi

  • Rodrigo Fernandes Alexandre

  • Maria Gabriela Abalos

  • Liping Huang

  • May 21, 2026

  • 0 min

Share

Clinical Scorecard: Assessment of Pneumococcal Disease Impact in Children Attributable to Serotypes Addressed by Various Conjugate Vaccines in Five Latin American Nations

At a Glance

CategoryDetail
Condition
Key MechanismsImpact of pneumococcal conjugate vaccines (PCVs) on disease burden, including higher-valent vaccines.
Target Population
Care Setting

Key Highlights

  • Clarify the burden caused by serotypes in PCV15 and PCV20 compared to PCV10 and PCV13.

Guideline-Based Recommendations

Diagnosis

    Management

    • Implement higher-valent PCVs (PCV15, PCV20) to address remaining disease burden, with specific age recommendations.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        Higher-valent vaccines may reduce morbidity and mortality from pneumococcal disease, with specific expected outcomes.

        Clinical Best Practices

        • Ensure high vaccination coverage with PCV10 and PCV13, and implement strategies to improve uptake of PCV15 and PCV20.

        Related Resources & Content

        Original Source(s)

        Related Content